Skip to main content

Day: June 2, 2021

BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor

12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors(1) Top Responder: 21.4 months survival plus 100% resolution of ‘eye-bulging’ orbital tumor Compares to 7.2-9.8 months survival in historical comparison treatment trials(2)BERKELEY, Calif. and VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today provides an update on the overall survival (OS) data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell’s lead candidate Bria-IMT™ as monotherapy and also in combination with...

Continue reading

Brookfield Infrastructure Announces Intention to Launch a Superior, Revised Cash and Share Offer Directly to Inter Pipeline Ltd. Shareholders, Valued at $19.75 per share, Closing in Approximately 20 days

Offer HighlightsAggregate cash and share-based consideration totaling C$19.75 per Inter Pipeline Ltd. (TSX: IPL) (“IPL” or the “Company”) share1, representing a 4.4% premium to the Pembina Pipeline Corporation (“Pembina”) share-based offer valued at C$18.91 per share as of market close on June 1, 2021. Cash component of the Offer represents 74% of the total consideration, compared to zero in the Pembina offer. Brookfield Infrastructure has received all regulatory and anti-trust approvals and can close as early as 10 business days from the filing date of the variation to our Offer. Preserves significant local Canadian jobs compared to IPL’s alternative cost synergy-driven transaction.BROOKFIELD, NEWS, June 02, 2021 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners L.P. (NYSE: BIP; TSX: BIP.UN), together with its institutional...

Continue reading

FreightHub, Inc. Announces Technology Collaboration with RC Control

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) — Hudson Capital Inc. (NASDAQ: HUSN) (Hudson Capital) announced that FreightHub, Inc. (Fr8Hub), a North American transportation logistics technology platform company focused on US-Mexico cross-border shipping with which Hudson Capital has signed a definitive Merger Agreement, is collaborating with RC Control to help alleviate one of the biggest challenges with US-Mexico cross border freight: seamless visibility. “The Fr8Hub Mobile App provides 24/7 visibility to our users and RC Control’s integration complements our mobile app to help give customers increased confidence that they will be able to have the same experience tracking their freight on either side of the US-Mexico border,” stated Javier Selgas, CEO of Fr8Hub. “Now our carriers, both in the US and Mexico, have multiple options for...

Continue reading

Helius Medical Technologies, Inc. Appoints Frederick Fantazzia as Vice President of Sales & Marketing, North America

NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021. “Fred is a dynamic leader with 16 years of sales and marketing experience in the field of neuromodulation, and a specific focus on developing the market for new neuromodulation technologies by building and leading high-quality sales team to raise awareness and facilitate commercial adoption,” said Dane Andreeff, Interim President and Chief Executive Officer of Helius. “We are pleased to welcome him to our leadership team and look forward to his contributions as we continue our pre-commercialization...

Continue reading

Lands’ End Announces First Quarter Fiscal 2021 Results

Net Revenue grew 48.1%; Global eCommerce grew revenue 44.4%, compared to the same period last yearNet Income of $2.6 million, compared to a Net loss of $20.6 million in the same period last yearAdjusted EBITDA increases $34.1 million to $22.5 million compared to the same period last yearRaises Fiscal 2021 Outlook DODGEVILLE, Wis., June 02, 2021 (GLOBE NEWSWIRE) —  Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the first quarter ended April 30, 2021. Fiscal First Quarter Financial Highlights:For the first quarter, net revenue was $321.3 million, an increase of 48.1% from $217.0 million in the first quarter of fiscal 2020 and an increase of 22.4% from $262.4 million in the first quarter of fiscal 2019.Global eCommerce net revenue was $260.0 million, an increase of 44.4% from $180.0 million in the first...

Continue reading

Global WholeHealth Partners Corp (GWHP-OTC) has Signed an Agreement With Dr. Vu Le to be the Medical Director for the CLIA WAIVED Mobile Laboratory

Global Will be Using All CLIA WAIVED Lab to Test for COVID 19 Antigen, Antibody, and the Other 15 Tests that are CLIA WAIVED that Global Carries; Company is Bringing Testing to Patients at Schools & Work SAN CLEMENTE, CA, June 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Global WholeHealth Partners Corp. (OTC: GWHP), a company that offers one of the largest lines of COVID 19 tests including SARS-CoV-2 viruses and that states that its Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses, today announced that they will be bringing their tests directly to the homes and offices of patients in need. To help implement this outreach program, the Company has signed an agreement with Dr. Vu Le to be the Medical Director for the Company’s CLIA WAIVED Mobile Laboratory. The Company...

Continue reading

Immune Therapeutics Announces Financing and Debt Restructuring Plan

Orlando, Florida, June 02, 2021 (GLOBE NEWSWIRE) — Immune Therapeutics Inc. (OTC-PINK: IMUND) (the “Company”) announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt. The Company received the term sheet from existing Immune Shareholders to provide the funds necessary to complete the restructuring of Immune. According to the agreement, the investors will lend a minimum of $700,000 and a maximum of $1,500,000 to the Company in exchange for non-convertible promissory notes bearing interest at 5%. In connection with the transactions above, to the extent a noteholder holds any warrants to purchase shares of common stock of Borrower (“Warrants”), Lender shall have the right...

Continue reading

Announcing Olink Signature Q100: facilitating access for researchers to Olink technology with a benchtop system dedicated to multiplex protein biomarker measurement

UPPSALA, Sweden, June 02, 2021 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now taking orders for Olink® Signature Q100, to allow more researchers access to Olink technology and high-quality proteomics data. Olink Signature Q100 is an affordable new benchtop system designed for readout of Olink® Target and Olink® Focus protein biomarker panels. In parallel with the successful implementation of the Olink Explore platform for high-throughput protein biomarker discovery with Next-Generation Sequencing (NGS) readout, Olink continues to invest in and develop its portfolio of more targeted solutions for protein biomarker research, based on readout with microfluidic quantitative PCR (qPCR). Until now, readout of Olink’s Target and Focus panels has been exclusively carried out using the multi-functional...

Continue reading

Rapid Therapeutic Prepares to file Investigational New Drug Application for its CBD Metered Dose Inhaler with FDA

DALLAS, June 02, 2021 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announced today it has executed two (2) contracts to conduct Phase 1 human clinical trials of its flagship metered dose inhaler (MDI) containing Cannabidiol (CBD). RTSL entered into these two contracts in preparation for filing an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA). Filing is anticipated in the next 30 days. An IND is a request for the FDA’s authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. RTSL engaged Dr. Charles Powell, MD who is the Chief...

Continue reading

Tyson Foods Announces Donnie King to Succeed Dean Banks as President and CEO

SPRINGDALE, Ark., June 02, 2021 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN) announced today that Chief Operating Officer Donnie King has been named President and Chief Executive Officer, effective immediately. Current President and CEO Dean Banks is leaving the company and board for personal reasons. “The board and I know that Donnie has a deep understanding of our business, values and culture and the solid leadership skills needed to continue to implement our strategy and deliver strong results,” said John H. Tyson, chairman of the board. “We want to express our appreciation to Dean for his contributions as a board member and executive.” “Being a part of Tyson Foods has been a very rewarding experience,” said Banks. “Upon deep personal reflection, and discussions with my family, the board, and my colleagues, I believe that...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.